





Supplementary Figure 1. A. The plasmid #48688 contains the following elements: 5' LTR, Chimeric Rous sarcoma virus (RSV)-HIV 5' long terminal repeat; SD, splice donor; ψ=packaging signal; GA, truncated gag sequence; RRE, Rev-Responsive Element; SA, splice acceptor; cppt, central polypurine tract; UbC-P, Ubiquitin C promoter; dTomato, red fluorescent dimer tomato (with 5' Kozak sequence, GCCACC[ATGG]); P2A, porcine teschovirus 2A element; adapted from Szymczak et al (2004); luc, firefly luciferase; T2A, Thosea asigna virus 2A element adapted from Szymczak et al (2004); WPRE, woodchuck hepatitis virus posttranscriptional regulatory element and 3'SIN-LTR, U3-deleted 3' LTR to generate self-inactivating (SIN) vector. B. Quantification of mRNA expression of M1- and M2-related genes in BMDM-CSF-1, BMDM-LM8, and BMDM-NFSa. HPRT was uses as an internal control. Data are presented as mean ± SD (n = 3 per group). *, $p < 0.01$; **, $p < 0.001$; ***, $p < 0.0001$; Student *t* test. C. Left; surface marker profile of BMDM-TAMs produced by CSF-1/CMG, TCM/LM8, and TCM/NFSa, assessed by flow cytometry. A, Cellular distribution of $CD45^+/CD11b^+$ cells. PLX3397 treatment did not affect the cellular distribution of $CD45^+/CD11b^+$ cells in BMDMs-CSF-1, BMDMs-LM8, and BMDMs-NFSa. Right; Cellular distribution of $CD45^+CD11b^+CD206^+/CD45^+CD11b^+CD80^+$ cells. The number of $CD45^+CD11b^+CD206^+$ decreased by PLX3397 at a dose of 500 nM in BMDMs-CSF-1and BMDMs-NFSa.